Semaglutide and Pregnancy: Safety, Evidence & Provider Guidance

Last reviewed: May 23, 2026

Last updated: May 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide use during pregnancy is not recommended and should be discontinued if pregnancy occurs, according to current prescribing guidance and clinical consensus. No controlled human studies have evaluated semaglutide safety in pregnant women, making evidence-based decision-making a cornerstone of obstetric care.

For patients who are pregnant, planning pregnancy, or nursing, treatment decisions require individual medical evaluation with an obstetrician and endocrinologist. PlexusDx supports precision-wellness conversations by helping providers understand individual metabolic factors that may influence longer-term weight and metabolic management strategies.

Current Clinical Evidence on Semaglutide and Pregnancy

Semaglutide has not been adequately studied in pregnant humans. Animal reproduction studies show fetal toxicity at doses multiples of the human dose, though these findings do not directly translate to clinical risk. FDA pregnancy category classification guides prescribing but does not eliminate uncertainty.

Observational data and case reports exist in medical literature, but prospective controlled trials are lacking. This evidence gap means clinical decisions rely on theoretical risk assessment, gestational timing of exposure, and individual maternal health factors rather than definitive safety data.

Risk-Benefit Framework: When Providers Reassess Semaglutide Use

Providers weigh maternal metabolic health—including gestational diabetes risk, pre-existing diabetes, and obesity-related complications—against theoretical fetal exposure risk. This individualized framework differs significantly from a blanket contraindication, and clinical judgment dominates decision-making.

Clinical Scenario	Typical Provider Consideration
Unplanned pregnancy while on semaglutide	Discontinue immediately; establish obstetric care; monitor glucose if diabetic
Pre-existing Type 2 diabetes requiring glycemic control	May continue metformin, insulin, or other agents; reassess semaglutide individually
Gestational diabetes or high-risk status	Insulin or metformin preferred; semaglutide generally avoided unless maternal risk extreme
Severe obesity with metabolic complications pre-pregnancy	Weight management deferred to postpartum period; focus shifts to maternal and fetal health

Discontinuation Timeline and Metabolic Monitoring

If semaglutide is discontinued upon pregnancy confirmation, most clinicians recommend allowing clearance of the medication from the system before conception if pregnancy is planned. GLP-1 receptor agonists have varying half-lives; weekly semaglutide may require several weeks to clear substantially.

During pregnancy, maternal glucose monitoring becomes critical if diabetes exists. Insulin and metformin remain first-line agents for gestational and Type 2 diabetes in pregnancy. Postpartum, treatment options—including compounded semaglutide—can be reconsidered once breastfeeding status is determined.

Nursing, Postpartum Restart, and Personalized Pathways

Semaglutide excretion into breast milk is unknown; most providers recommend avoiding semaglutide during active breastfeeding as a precaution. Postpartum, once nursing is complete or if not breastfeeding, metabolic management can resume with updated clinical assessment and provider guidance.

Genetic factors influencing GLP-1 receptor responsiveness and metabolic pathways may inform postpartum treatment choices, but pregnancy safety decisions are purely clinical and do not depend on genetic testing. Consulting with your provider about long-term metabolic management after pregnancy supports informed, personalized care.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines variations in GLP1R, GIPR, FTO, and MC4R genes that may help provide context for how individuals respond to GLP-1 therapies in non-pregnancy settings. These genetic predispositions should be interpreted with a qualified healthcare provider and are not relevant to pregnancy safety decisions.

Pregnancy safety assessment relies entirely on clinical and obstetric evaluation, not genetic testing. However, understanding your GLP-1 receptor and metabolic genetics may support more informed conversations about post-pregnancy weight and metabolic management options when semaglutide or other agents can be safely reconsidered.

After pregnancy and breastfeeding, personalized treatment decisions can incorporate individual metabolic factors. PlexusDx encourages patients to work with their healthcare provider to develop a comprehensive strategy that aligns genetic insights with clinical evidence and personal health goals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.